Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen - guidance (TA316)

NICE Accredited

National Institute for Health and Care Excellence - NICE
Publication date:
23 July 2014


Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.

Guidance development process

How we develop NICE technology appraisal guidance

Is this guidance up to date?

We reviewed the evidence in December 2017. We found nothing new that affects the recommendations in this guidance. We are incorporating the guidance into the update of NICE’s clinical guideline on prostate cancer (CG175).

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.